• Wiley Online Library will be disrupted on 18 May from 10:00-12:00 BST (05:00-07:00 EDT) for essential maintenance
  • Please log in or register to access this feature.
You have free access to this content

The global burden of hepatitis C

  1. Daniel Lavanchy

Article first published online: 21 JAN 2009

DOI: 10.1111/j.1478-3231.2008.01934.x

Issue

Liver International

Liver International

Special Issue: International Conference of the Management of Patients with Viral Hepatitis, Paris, 19-20 January 2009

Volume 29, Issue Supplement s1, pages 74–81, January 2009

Additional Information

How to Cite

Lavanchy, D. (2009), The global burden of hepatitis C. Liver International, 29: 74–81. doi: 10.1111/j.1478-3231.2008.01934.x

Author Information

  1. World Health Organization (WHO), Genève, Switzerland

*Correspondence Daniel Lavanchy, MD, MHEM, World Health Organization (WHO), HSE/EPR/BDP, 20, avenue Appia, CH-1211 Genève 27, Switzerland Tel: +41 22 791 26 56 Fax: +41 22 791 46 66 e-mail: lavanchyd@who.int

Publication History

  1. Issue published online: 21 JAN 2009
  2. Article first published online: 21 JAN 2009
  3. Received 19 August 2008Accepted 10 November 2008

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (178K)

References

  • 1
    Global surveillance and control of hepatitis C. Report of a WHO consultation organized in collaboration with the viral hepatitis prevention board, Antwerp, Belgium. J Viral Hepat 1999; 6: 35–47.
  • 2
    World Health Organization. Hepatitis C – global prevalence (update). Wkly Epidemiol Rec 2000; 75: 18–9.
  • 3
    World Health Organization. Hepatitis C – global prevalence (update). Wkly Epidemiol Rec 1999; 74: 425–7.
  • 4
    World Health Organization. Hepatitis C: global prevalence (update). Wkly Epidemiol Rec 1997; 72: 341–4.
  • 5
    Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558–67.
  • 6
    Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45: 529–38.
  • 7
    Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002, Ann Intern Med 2006; 144: 705–14.
  • 8
    Sagnelli E, Stroffolini T, Mele A, et al. The importance of HCV on the burden of chronic liver disease in Italy: a multicenter prevalence study of 9,997 cases. J Med Virol 2005; 75: 522–7.
  • 9
    The Global Burden of Hepatitis C Working Group. Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol 2004; 44: 20–9.
  • 10
    Yousuf M, Nakano Y, Tanaka E, Sodeyama T, Kiyosawa K. Persistence of viremia in patients with type-C chronic hepatitis during long-term follow-up. Scand J Gastroenterol 1992; 27: 812–6.
  • 11
    Donahue JG, Munoz A, Ness PM, et al. The declining risk of post-transfusion hepatitis C virus infection. N Engl J Med 1992; 327: 369–73.
  • 12
    Wasley A, Alter M. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 2000; 20: 1–16.
  • 13
    Garfein RS, Vlahov D, Galai N, Doherty MC, Nelson KE. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health 1996; 86: 655–61.
  • 14
    Hutin YJ, Chen RT. Injection safety: a global challenge. Bull World Health Organ 1999; 77: 787–8.
  • 15
    Medhat A, Shehata M, Magder LS, et al. Hepatitis C in a community in Upper Egypt: risk factors for infection. Am J Trop Med Hyg 2002; 66: 633–8.
  • 16
    Stoszek SK, Abdel-Hamid M, Narooz S, et al. Prevalence of and risk factors for hepatitis C in rural pregnant Egyptian women. Trans R Soc Trop Med Hyg 2006; 100: 102–7.
  • 17
    Simonsen L, Kane A, Lloyd J, Zaffran M, Kane M. Unsafe injections in the developing world and transmission of bloodborne pathogens: a review. Bull World Health Organ 1999; 77: 789–800.
  • 18
    Kane A, Lloyd J, Zaffran M, Simonsen L, Kane M. Transmission of hepatitis B, hepatitis C and human immunodeficiency viruses through unsafe injections in the developing world: model-based regional estimates. Bull World Health Organ 1999; 77: 801–7.
  • 19
    Frank C, Mohamed MK, Strickland GT, et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 2000; 355: 887–91.
  • 20
    Meky FA, Stoszek SK, Abdel-Hamid M, et al. Active surveillance for acute viral hepatitis in rural villages in the Nile Delta. Clin Infect Dis 2006; 42: 628–33.
  • 21
    Kidney disease: improving global outcomes. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int 2008; 73 (Suppl. 109): S1–99.
  • 22
    Crofts N, Jolley D, Kaldor J, Van Beek I, Wodak A. Epidemiology of hepatitis C virus infection among injecting drug users in Australia. J Epidemiol Community Health 1997; 51: 692–7.
  • 23
    Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000; 90: 1562–9.
  • 24
    Seeff LB, Hoofnagle JH. The national institutes of health consensus development conference management of hepatitis C 2002. Clin Liver Dis 2003; 7: 261–87.
  • 25
    Armstrong GL, Alter MJ, McQuillan GM, Margolis HS. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology 2000; 31: 777–82.
  • 26
    Alter MJ. Epidemiology of hepatitis C. Hepatology 1997; 26 (Suppl. 1): 62S–5S.
    Direct Link:
  • 27
    Buti M, Medina M, Casado MA, et al. A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naive patients with chronic hepatitis C. Aliment Pharmacol Ther 2003; 17: 687–94.
    Direct Link:
  • 28
    Siebert U, Sroczynski G, Rossol S, et al. Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut 2003; 52: 425–32.
  • 29
    Buti M, San Miguel R, Brosa M, et al. Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C. J Hepatol 2005; 42: 639–45.
  • 30
    Deuffic-Burban S, Wong JB, Valleron AJ, et al. Comparing the public health burden of chronic hepatitis C and HIV infection in France. J Hepatol 2004; 40: 319–26.
  • 31
    Wong JB. Interferon treatment for chronic hepatitis B or C infection: costs and effectiveness. Acta Gastroenterol Belg 1998; 61: 238–42.
  • 32
    Bennett WG, Inoue Y, Beck JR, et al. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997; 127: 855–65.
  • 33
    Sennfalt K, Reichard O, Hultkrantz R, Wong JB, Jonsson D. Cost-effectiveness of interferon alfa-2b with and without ribavirin as therapy for chronic hepatitis C in Sweden. Scand J Gastroenterol 2001; 36: 870–6.
  • 34
    Younossi ZM, Singer ME, McHutchison JG, Shermock KM. Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C. Hepatology 1999; 30: 1318–24.
    Direct Link:
  • 35
    Gordon FD. Cost-effectiveness of screening patients for hepatitis C. Am J Med 1999; 107: 36S–40S.
  • 36
    MMWR/CDC. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for disease control and prevention. Morb Mortal Wkly Rep 1998; 47 (RR-19): 1–39.
  • 37
    Alter MJ, Kuhnert WL, Finelli L. Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. Centers for disease control and prevention. Morb Mortality Wkly Rep Recomm Rep 2003; 52 (RR-3): 1–13, 5; quiz CE1–4.
  • 38
    Fischer LR, Tope DH, Conboy KS, et al. Screening for hepatitis C virus in a health maintenance organization. Arch Intern Med 2000; 160: 1665–73.
  • 39
    Shah BB, Wong JB. The economics of hepatitis C. Clin Liver Dis 2006; 10: 717–34.
  • 40
    Freeman AJ, Dore GJ, Law MG, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001; 34 (Part 1): 809–16.
    Direct Link:
  • 41
    Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. Hepatology 1997; 26 (Suppl. 1): 15S–20S.
  • 42
    Kew M. Hepatitis C virus and hepatocellular carcinoma in developing and developed countries. Viral Hepat Rev 1998; 4: 259–69.
  • 43
    Tanaka H, Imai Y, Hiramatsu N, et al. Declining incidence of hepatocellular carcinoma in Osaka, Japan, from 1990 to 2003. Ann Intern Med 2008; 148: 820–6.
  • 44
    Arii S, Yamaoka Y, Futagawa S, et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology 2000; 32: 1224–9.
  • 45
    Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med 1999; 131: 174–81.
  • 46
    Alter HJ, Conry-Cantilena C, Melpolder J, et al. Hepatitis C in asymptomatic blood donors. Hepatology 1997; 26 (Suppl. 1): 29S–33S.
    Direct Link:
  • 47
    Alter HJ. HCV natural history: the retrospective and prospective in perspective. J Hepatol 2005; 43: 550–2.
  • 48
    Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 1999; 340: 1228–33.
  • 49
    Wiese M, Grungreiff K, Guthoff W, et al. Outcome in a hepatitis C (genotype 1b) single source outbreak in Germany – a 25-year multicenter study. J Hepatol 2005; 43: 590–8.
  • 50
    Powell EE. How host and viral factors affect fibrosis progression in HCV. 3rd Australasian Conference on Hepatitis C, Melbourne, 2002.
  • 51
    Adinolfi L, Gambardella M, Andredeana A, et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33: 1358–64.
    Direct Link:
  • 52
    Hourigan L, Macdonald G, Purdie D, et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 1999; 29: 1215–9.
    Direct Link:
  • 53
    Hickman IJ, Clouston AD, Macdonald GA, et al. Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut 2002; 51: 89–94.
  • 54
    Sanchez-Quijano A, Andreu J, Gavilan F, et al. Influence of human immunodeficiency virus type 1 infection on the natural course of chronic parenterally acquired hepatitis C. Eur J Clin Microbiol Infect Dis 1995; 14: 949–53.
  • 55
    Dore GJ, Freeman AJ, Law M, Kaldor J. Is severe liver disease a common outcome for people with chronic hepatitis C? J Gastroenterol Hepatol 2002; 17: 423–30.
    Direct Link:
  • 56
    Dore GJ, Cooper DA. The impact of HIV therapy on co-infection with hepatitis B and hepatitis C viruses. Curr Opin Infect Dis 2001; 14: 749–55.
  • 57
    Tsai JF, Jeng JE, Ho MS, et al. Effect of hepatitis C and B virus infection on risk of hepatocellular carcinoma: a prospective study. Br J Cancer 1997; 76: 968–74.
  • 58
    Xia X, Luo J, Bai J, Yu R. Epidemiology of hepatitis C virus infection among injection drug users in China: systematic review and meta-analysis. Public Health 2008; 122: 990–1003.
  • 59
    Bukhtiari N, Hussain T, Iqbal M, et al. Hepatitis B and C single and co-infection in chronic liver disease and their effect on the disease pattern. J Pak Med Assoc 2003; 53: 136–40.
  • 60
    Bonino F, Oliveri F, Colombatto P, Brunetto MR. Impact of interferon-alpha therapy on the development of hepatocellular carcinoma in patients with liver cirrhosis: results of an international survey. J Viral Hepat 1997; 4 (Suppl. 2): 79–82.
  • 61
    Harris DR, Gonin R, Alter HJ, et al. The relationship of acute transfusion-associated hepatitis to the development of cirrhosis in the presence of alcohol abuse. Ann Intern Med 2001; 134: 120–4.
  • 62
    Wiley TE, McCarthy M, Breidi L, Layden TJ. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology 1998; 28: 805–9.
    Direct Link:
  • 63
    Hezode C, Roudot-Thoraval F, Nguyen S, et al. Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology 2005; 42: 63–71.
    Direct Link:
  • 64
    Pessione F, Ramond MJ, Njapoum C, et al. Cigarette smoking and hepatic lesions in patients with chronic hepatitis C. Hepatology 2001; 34: 121–5.
    Direct Link:
  • 65
    Dev A, Patel K, Conrad A, Blatt LM, McHutchison JG. Relationship of smoking and fibrosis in patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2006; 4: 797–801.
  • 66
    Fujita Y, Shibata A, Ogimoto I, et al. The effect of interaction between hepatitis C virus and cigarette smoking on the risk of hepatocellular carcinoma. Br J Cancer 2006; 94: 737–9.
  • 67
    World Health Organization. Hepatitis C: global prevalence. Wkly Epidemiol Rec 1997; 72: 65–9.
  • 68
    McHutchison JG, Patel K, Schiff ER, et al. Clinical trial: interferon alpha-2b continuous long-term therapy vs. repeated 24-week cycles for re-treating chronic hepatitis C. Aliment Pharmacol Ther 2008; 27: 422–32.
  • 69
    Maylin S, Martinot-Peignoux M, Moucari R, et al. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology 2008; 135: 821–9.
  • 70
    Castillo I, Rodriguez-Inigo E, Lopez-Alcorocho JM, et al. Hepatitis C virus replicates in the liver of patients who have a sustained response to antiviral treatment. Clin Infect Dis 2006; 43: 1277–83.
  • 71
    Bizollon T, Ahmed SN, Radenne S, et al. Long term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon–ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence. Gut 2003; 52: 283–7.
  • 72
    Veldt BJ, Saracco G, Boyer N, et al. Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy. Gut 2004; 53: 1504–8.
  • 73
    Bruno S, Silini E, Crosignani A, et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology 1997; 25: 754–8.
  • 74
    Marcellin P, Boyer N, Gervais A, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997; 127: 875–81.
  • 75
    Shiratori Y, Imazeki F, Moriyama M, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000; 132: 517–24.
  • 76
    Heathcote EJ. Antiviral therapy: chronic hepatitis C. J Viral Hepat 2007; 14 (Suppl. 1): 82–8.
  • 77
    Bowden DS, Berzsenyi MD. Chronic hepatitis C virus infection: genotyping and its clinical role. Future Microbiol 2006; 1: 103–12.
  • 78
    Martinot-Peignoux M, Roudot-Thoraval F, Mendel I, et al. Hepatitis C virus genotypes in France: relationship with epidemiology, pathogenicity and response to interferon therapy. The GEMHEP. J Viral Hepat 1999; 6: 435–43.
  • 79
    Roffi L, Ricci A, Ogliari C, et al. HCV genotypes in Northern Italy: a survey of 1368 histologically proven chronic hepatitis C patients. J Hepatol 1998; 29: 701–6.
  • 80
    Webster G, Barnes E, Brown D, Dusheiko G. HCV genotypes – role in pathogenesis of disease and response to therapy. Baillieres Best Pract Res Clin Gastroenterol 2000; 14: 229–40.
  • 81
    Murray KF, Finn LS, Taylor SL, Seidel KD, Larson AM. Liver histology and alanine aminotransferase levels in children and adults with chronic hepatitis C infection. J Pediatr Gastroenterol Nutr 2005; 41: 634–8.
  • 82
    Freeman AJ, Law MG, Kaldor JM, Dore GJ. Predicting progression to cirrhosis in chronic hepatitis C virus infection. J Viral Hepat 2003; 10: 285–93.
    Direct Link:
  • 83
    Helbling B, Overbeck K, Gonvers JJ, et al. Host – rather than virus-related factors reduce health-related quality of life in hepatitis C virus infection. Gut 2008; 57: 1597–603.
  • 84
    Nakamura J, Terajima K, Aoyagi Y, Akazawa K. Cost-effectiveness of the national screening program for hepatitis C virus in the general population and the high-risk groups. Tohoku J Exp Med 2008; 215: 33–42.
  • 85
    Thompson Coon J, Rogers G, Hewson P, et al. Surveillance of cirrhosis for hepatocellular carcinoma: a cost–utility analysis. Br J Cancer 2008; 98: 1166–75.
  • 86
    Castelnuovo E, Thompson-Coon J, Pitt M, et al. The cost-effectiveness of testing for hepatitis C in former injecting drug users. Health Technol Assess 2006; 10: iii–iv, ix–xii, 1–93.
  • 87
    Cleveland JL, Barker L, Gooch BF, Beltrami EM, Cardo D. Management of occupational blood exposures. J Am Dent Assoc 2002; 133: 1630.
View Full Article (HTML) Get PDF (178K)